Horizon3.ai Gains FedRAMP High Authorization, Delivering on Its Commitment to Secure the Public Sector
15.5.2025 14:00:00 CEST | Business Wire | Press Release
Horizon3.ai, the global leader in offensive security, today announced it has gained Federal Risk and Authorization Management Program (FedRAMP®) High Authorization, unlocking the ability to support even the most security-sensitive federal missions. This milestone fulfills Horizon3.ai’s previously announced commitment to bring proof-based security to government agencies operating at the highest levels of compliance and risk exposure.
Horizon3.ai’s newly authorized platform, NodeZero Federal™, is now available to federal agencies under the FedRAMP High baseline. Built upon the proven commercial version of the NodeZero® Offensive Security Platform, NodeZero Federal™ is designed specifically to meet the heightened security and compliance demands of government environments. With this authorization in place, Horizon3.ai becomes the first and only cybersecurity vendor authorized to deliver continuous, autonomous pentesting within this strict regulatory framework.
“We built NodeZero to help defenders find and fix vulnerabilities before attackers exploit them—and with the FedRAMP High authorization, we’re now able to proactively secure critical federal systems,” said Snehal Antani, CEO and Co-founder of Horizon3.ai. “Our roots are in National Security, and with cyber warfare evolving at an unprecedented pace, we’re committed to improving the cyber resilience of the nation’s digital infrastructure, with support for Secret and Top Secret systems as our next major focus areas.”
This authorization builds on Horizon3.ai’s success with Federal partners, such as the NSA Cybersecurity Collaboration Center (CCC) program. As part of CCC, Horizon3.ai powers the NSA’s Continuous Autonomous Penetration Testing (CAPT) program, where Defense Industrial Base (DIB) suppliers use NodeZero to act as nation-state-level adversaries, identify and prioritize real attack paths, and continuously validate their defenses.
“With our FedRAMP High authorization, critical suppliers and federal agencies can verify and improve their cybersecurity posture, ensuring that limited resources are focused on fixing problems that truly matter," said Matt Hartley, CRO at Horizon3.ai. "These agencies can find, fix, and verify the remediation of CISA Known Exploitable Vulnerabilities (KEV) at scale, ensure their security operations center is effectively detecting and stifling attacks, and that security tools are tuned correctly. Offense drives defense, and no one knows this better than our US Federal customers.”
NodeZero Federal helps agencies streamline compliance with key cybersecurity mandates, including NIST SP 800-53—the foundational control framework behind FedRAMP—as well as evolving OMB policies and Executive Orders that require Zero Trust architecture, Cybersecurity Maturity Model Certification (CMMC) 2.0 for supply chain assurance, and participation in Continuous Diagnostics and Mitigation (CDM) programs.
For more information about Horizon3.ai’s NodeZero Federal™ and its FedRAMP High capabilities, visit their website.
About Horizon3.ai
The NodeZero® Offensive Security Platform by Horizon3.ai drives continuous exposure management across production infrastructure. With NodeZero, customers overcome barriers of limited security talent and infrequent, expensive penetration testing. They stay ahead of a rapidly-evolving threat landscape with autonomous pentesting, emerging threat intelligence, threat detection, and unified data and reporting. Founded in 2019 by former industry leaders and U.S. National Security veterans, Horizon3.ai solves diverse use cases across all industries.
Follow Horizon3.ai on LinkedIn and X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250515365494/en/
Contacts
Media:
Ed Kraft
SourceCode Communications
horizon3@sourcecodecomms.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press Release
Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Malaysia 2026–2027 (VM2026–2027), this partnership merges Tourism Malaysia’s destination marketing with Alipay+’s global wallet ecosystem and AI capabilities. It aims to create a highly intelligent digital journey, connecti
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press Release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe atopic dermatitis, sustained through Week 52.1 The results will be presented at The Pediatric Dermatology Research Alliance (PeDRA) Annual Conference. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014705800/en/ Up to 25% of children are affected by atopic dermatitis - the most common inflammatory skin disorder in this population - and around one-third of these children have moderate-to-severe disease.11,12 Atopic dermatitis creates a high burden for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school, and social confidence.2-8 Despite the high prevalence and significant burden, treatment options are
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press Release
Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re excited at the potential to fundamentally change how NT1 is managed across Japan and China,” said Giles Platford, president, International, Takeda. “We’ve heard from patients how ORZEYFUL has improved their daily functioning and quality of life, enormously meaningful outcomes for a condition known to impact many aspects of a person’s life, including work, education and social interactions.”1,2,3,4,5 NT1 is a chronic, rare neurological disease driven by orexin deficiency. People experience a range of symptoms including excessive daytime sleepiness, cataplexy (sudden loss of muscle tone), disr
Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press Release
Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to expand treatment options for patients with IBD.2,3 On October 18, Celltrion will host a symposium titled "Navigating the Treatment Journey with Subcutaneous Infliximab Across Clinical Scenarios," Chaired by Professor Peter M. Irving of King's College London, UK, a leading IBD expert. Celltrion will also host two MTE sessions at its booth. In the firs
ProcureTEX Returns for Its Second Year, Bringing AI and Best-of-Breed Procurement Technology to Amsterdam14.10.2026 18:26:00 CEST | Press Release
ProcureTEX, the community-driven event for best-of-breed procurement technology, returns for its second year on November 3, 2026, at Circa in Amsterdam. Following its London debut in 2025, the event sharpens its focus on how AI is reshaping procurement. It will bring together over 250 procurement leaders and digital transformation teams from large enterprises, with vetted best-of-breed technology providers, to see AI agents and interoperable tools working together on real enterprise challenges. Co-founded by Beroe, Keelvar and Zip, the event is built on the belief that the future of procurement isn’t a monolithic all-in-one suite, but an ecosystem of best-of-breed tools working together. It is designed for procurement and enterprise leaders seeking scalable, modern solutions, whether they’re driving transformation, frustrated with outdated tools, or looking to connect with peers solving similar problems and putting AI to work. Renowned technology analyst and former Andreessen Horowitz
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom